Skip to main content

Table 2 Overall survival, progression free survival and observed complete response univariate analysis

From: DPD status and fluoropyrimidines-based treatment: high activity matters too

  Overall Survival Progression free survival Observed complete response
Variable Modality HR CI95% p-Cox HR CI95% p-Cox OR CI95% p-RegLog
DPD activity Low < 0.30 1 REF. 1 REF. 1
High ≥0.30 3.1 [1.50–6.50] 0.00188 2.40 [1.40–4.0] 0.00158 0.34 [0.13–0.87] 0.022
Sex Female 1 REF. 1 REF. 1
Male 1.8 [0.92–3.50] 0.0888 1.4 [0.92–2.3] 0.115 0.87 [0.42–1.80] 0.7
Cancer location Digestive 1 REF. 1 REF. 1
Head and Neck 1.2 [0.42–3.60] 0.701 0.78 [0.31–2.0] 0.593 0.44 [0.089–2.1] 0.29
Breast 0.38 [0.14–1.00] 0.0613 0.68 [0.37–1.3] 0.219 0.71 [0.26–1.90] 0.49
Disease severity Local disease 1 REF. 1 REF. 1
Advanced disease 2.60 [1.00–6.80] 0.0462 2.2 [1.2–3.90] 0.00797 0.29 [0.11–0.74] 0.008
Other chemotherapy before FP No 1 REF. 1 REF. 1
Yes 1.2 [0.59–2.50] 0.606 2.1 [1.3–3.30] 0.00227 0.22 [0.09–0.54] 0.00069
FP-based treatment CAP 1 REF. 1 REF. 1
FU 0.90 [0.40–2.00] 0.798 1.5 [0.8–2.60] 0.217 0.83 [0.34–2.00] 0.68
FU_CAP 0.74 [0.28–1.90] 0.54 1.7 [0.87–3.3] 0.124 0.41 [0.14–1.20] 0.095
FP-based toxicity No 1 REF. 1 REF. 1
Yes 0.83 [0.41–1.70] 0.597 0.93 [0.58–1.5] 0.759 0.64 [0.31–1.30] 0.23
Surgery associated to FP No 1 REF. 1 REF. 1
Yes 0.46 [0.23–0.93] 0.0309 0.92 [0.55–1.6] 0.756 1.7 [0.74–3.80] 0.2
Radiotherapy associated to FP No 1 REF. 1 REF. 1
Yes 0.58 [0.29–1.20] 0.127 0.66 [0.41–1.1] 0.0797 1.2 [0.55–2.40] 0.7
Observed complete response during FP treatment No 1 REF.
Yes 0.098 [0.037–0.25] < 0.0001
Any recurrence No 1 REF.
Yes 5.00 [1.70–14.0] 0.00265
Age at FP-based treatment   1.04 [1.01–1.07] 0.0062 1.03 [1.01–1.05] 0.0069 0.98 [0.95–1.01] 0.21
Number of chemotherapy lines   0.93 [0.80–1.07] 0.31 1.08 [0.99–1.16] 0.065 0.86 [0.74–1.01] 0.06
Number of FP cycles   0.99 [0.96–1.02] 0.56 1.03 [1.02–1.05] < 0.001 0.98 [0.95–1.01] 0.30
  1. p-Cox p-value of Cox regression model, p-RegLog p-value regression logistique, HR Hazard ratio, CI95% confidence interval 95%, FP Fluoropyrimidine, REF reference value